CPT 0433U: EpiSwitch Prostate Screening Test (PSE)

CPT code 0433U designates the EpiSwitch® Prostate Screening Test (PSE), a proprietary laboratory assay that combines five DNA biomarkers with prostate specific antigen (PSA) measured from a whole blood specimen to estimate prostate cancer likelihood. As a PLA code, 0433U is unique to Oxford BioDynamics Inc. and signals a single-source molecular diagnostic service used in prostate cancer risk stratification. Nationally, PLA codes like 0433U matter because they identify discrete, manufacturer-specific tests that can affect coverage, coding clarity, and reimbursement pathways for precision diagnostics.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the test’s clinical purpose and service setting, a summary of payer coverage considerations, common billing modifiers used with laboratory services, and context for how a PLA-coded molecular test fits into diagnostic workflows. The publication also outlines typical site-of-service implications and what benchmarks and policy updates readers should expect to review regarding proprietary molecular assays. Data not available in the input will be noted where applicable.

Billing Code Overview

CPT code 0433U is a Proprietary Laboratory Analyses (PLA) code assigned to the EpiSwitch® Prostate Screening Test (PSE) from Oxford BioDynamics Inc. The assay uses a whole blood specimen to identify and quantify five DNA biomarkers combined with prostate specific antigen (PSA) level to predict the likelihood of prostate cancer. This code represents a specific, manufacturer- or lab-unique molecular diagnostic test designed for prostate cancer risk assessment.

Service type: Molecular diagnostic laboratory test (proprietary PLA)
Typical site of service: Clinical laboratory or outpatient phlebotomy collection site

Clinical Context

A 58-year-old man with an elevated prostate-specific antigen (PSA) level and ambiguous results from prior prostate cancer screening presents to a urology clinic. The urologist orders the EpiSwitch® Prostate Screening Test (PSE) to refine cancer risk assessment before deciding on prostate biopsy. A whole blood specimen is collected in the outpatient clinic or phlebotomy lab during the same visit. The sample is processed per laboratory instructions and shipped to the performing laboratory (Oxford BioDynamics Inc.) for proprietary analysis of five DNA biomarkers combined with the PSA value. Results are returned to the ordering urologist who integrates the report with clinical exam, PSA trend, digital rectal exam findings, and imaging (if available) to inform shared decision-making regarding the need for prostate biopsy or continued surveillance.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier	When no specific modifier is required or applicable for the service
`22`	Increased procedural services	When the laboratory service required substantially greater work than usual

Taxonomy Code	Specialty	Notes
2086S0200X	Urology	Ordering clinicians commonly are urologists managing elevated PSA and biopsy decisions
207Q00000X	Hematology/Oncology	Hematology/oncology specialists may order or interpret molecular diagnostic screening results
207RC0000X	Family Medicine	Primary care physicians may order the test as part of initial prostate cancer risk evaluation
363LF0000X	Clinical Laboratory	Performed and reported by the specialized laboratory offering the proprietary assay

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`R97.20`	Elevated prostate specific antigen [PSA], unspecified	Direct indication for ordering a prostate risk stratification test such as the PSE
`N40.0`	Benign prostatic hyperplasia with lower urinary tract symptoms	Common comorbidity that can raise PSA and prompt further risk assessment
`R33.9`	Retention of urine, unspecified	Lower urinary tract symptoms prompting urologic evaluation and possible PSA/PSE testing
`N45.1`	Orchitis and epididymitis	Inflammatory conditions that can affect PSA and confound prostate cancer screening considerations
`Z12.5`	Encounter for screening for malignant neoplasm of prostate	Screening context in which molecular risk stratification tests may be used

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`0433U`	EpiSwitch® Prostate Screening Test (PSE); identifies and quantifies five DNA biomarkers combined with PSA to predict prostate cancer likelihood	Primary proprietary laboratory analysis code for the test described
`80055`	Prosthetic evaluation; prostate-specific antigen (PSA), total	PSA measurement frequently obtained concurrently and used with the PSE test for risk calculation
`36415`	Collection of venous blood by venipuncture	Standard specimen collection procedure for a whole blood sample sent for the PSE assay
`84153`	Prostate specific antigen (PSA); total	Another commonly billed PSA-specific code used when reporting laboratory PSA testing associated with prostate cancer risk assessment

OpenPayer

Summary & Overview